Novartis's drug reduces heart failure deaths: study
Home page > News

Novartis's drug reduces heart failure deaths: study

www.reuters.com   | 24.09.2012.

ZURICH (Reuters) - Novartis's investigational medicine RLX030 reduced the number of deaths in patients with acute heart failure, the drugmaker said on Monday based on the results of a late-stage trial.
br />

RLX030 is form of the human hormone relaxin-2. Serelaxin acts by relaxing the blood vessels, leading to reduced stress on the heart and kidneys, the firm said in a statement.

(Reporting by Catherine Bosley)


Comments (0) Add Your comment Add news < Previous news Next news >






  Add your news >>>